Shares of biopharmaceutical company Ariad Pharmaceuticals, Inc. are higher by more than 4% in pre-market trading.
On Monday Ariad announced a deal with MolecularMD to develop a diagnostic test for genetic mutations related to leukemia.
ARIA stock price is currently trading at $7.50 a share, up 29 cents (4.02%) in the pre-market.
Ariad Pharmaceuticals, Inc.
